首次人体CLDN18.2功能性诊断PET显像实现消化系统肿瘤全身靶点定位与病灶检测
本研究为正在进行的开放标签、单臂、首次人体0期试验(NCT04883970),纳入17例病理确诊的消化系统肿瘤患者(胃癌12例、胰腺癌4例、胆管癌1例),评估124I-18B10(10L)示踪剂的安全性及全身CLDN18.2表达PET功能显像的可行性。结果显示该示踪剂制备成功,临床前研究显示高亲和力(Kd=4.11 nM),患者中耐受性良好且剂量学可接受,能清晰显示大多数过表达CLDN18.2的病灶。
要点
- 124I-18B10(10L)在临床前研究中显示高亲和力(Kd=4.11 nM)及CLDN18.2特异性。
- 17例消化系统肿瘤患者中,124I-18B10(10L) PET显像安全性良好,剂量学可接受。
- 肿瘤病灶124I-18B10(10L)摄取SUVmax范围为0.4至19.5,能清晰显示大多数过表达CLDN18.2的病灶。
核心结论
- 124I-18B10(10L)成功制备,临床前研究显示高结合亲和力和CLDN18.2特异性。
- 作为首次人体CLDN18.2 PET示踪剂,124I-18B10(10L)安全性良好、剂量学可接受,能清晰显示大多数过表达CLDN18.2的病灶。
研究设计与样本
- 正在进行的开放标签、单臂、首次人体0期试验(NCT04883970),纳入病理确诊的消化系统肿瘤患者。
- 124I-18B10(10L)探针人工合成,先后进行体外模型细胞测试、临床前实验(结合亲和力与特异性靶向能力)及患者PET显像。
- 患者在一周内完成124I-18B10(10L) PET/CT或PET/MR及18F-FDG PET检查。
主要发现
- 124I-18B10(10L)成功构建,放射化学产率超过95%。
- 临床前实验显示该探针在生理盐水中稳定性高,在CLDN18.2过表达细胞中亲和力高(Kd=4.11 nM)。
- 共纳入17例患者,包括胃癌12例、胰腺癌4例、胆管癌1例。
- 124I-18B10(10L)在脾和肝中高摄取,在骨髓、肺、胃和胰腺中轻度摄取。
- 肿瘤病灶中示踪剂摄取SUVmax范围为0.4至19.5;与接受过CLDN18.2靶向治疗的病灶相比,未治疗病灶的124I-18B10(10L)摄取显著更高。
关键数值与推荐
- 临床前结合亲和力Kd=4.11 nM(CLDN18.2过表达细胞)。
- 放射化学产率超过95%。
- 肿瘤病灶124I-18B10(10L)摄取SUVmax范围0.4至19.5。
- 17例患者中胃癌12例、胰腺癌4例、胆管癌1例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Claudin 18.2 (CLDN18.2) is a reliable target for lesion detection and could have clinical implications for epithelial tumors, especially digestive system neoplasms. However, there is no predictive technology for accurate whole-body mapping of CLDN18.2 expression in patients. This study assessed the safety of the 124I-18B10(10L) tracer and the feasibility of mapping whole-body CLDN18.2 expression using PET functional imaging. METHODS: The 124I-18B10(10L) probe was synthesized manually, and preclinical experiments including binding affinity and specific targeting ability were conducted after testing in vitro model cells. Patients with pathologically confirmed digestive system neoplasms were enrolled in an ongoing, open-label, single-arm, first-in-human (FiH) phase 0 trial (NCT04883970). 124I-18B10(10L) PET/CT or PET/MR and 18F-FDG PET were performed within one week. RESULTS: 124I-18B10(10L) was successfully constructed with an over 95% radiochemical yield. The results of preclinical experiments showed that it had high stability in saline and high affinity in CLDN18.2 overexpressing cells (Kd = 4.11 nM). Seventeen patients, including 12 with gastric cancers, 4 with pancreatic cancers, and 1 with cholangiocarcinoma were enrolled. 124I-18B10(10L) displayed high uptake in the spleen and liver, and slight uptake in the bone marrow, lung, stomach and pancreas. The tracer uptake SUVmax in tumor lesions ranged from 0.4 to 19.5. Compared with that in lesions that had been treated with CLDN18.2-targeted therapy, 124I-18B10(10L) uptake was significantly higher in lesions that had not. Regional 124I-18B10(10L) PET/MR in two patients showed high tracer uptake in metastatic lymph nodes. CONCLUSIONS: 124I-18B10(10L) was successfully prepared and exhibited a high binding affinity and CLDN18.2 specificity in preclinical studies. As an FiH CLDN18.2 PET tracer, 124I-18B10(10L) was shown to be safe with acceptable dosimetry and to clearly reveal most lesions overexpressing CLDN18.2. TRIAL REGISTRATION: NCT04883970; URL: https://register. CLINICALTRIALS: gov/ . Registered 07 May 2021.
引用
- Wang S, Qi C, Ding J, et al. First-in-human CLDN18.2 functional diagnostic pet imaging of digestive system neoplasms enables whole-body target mapping and lesion detection. Eur J Nucl Med Mol Imaging. 2023. PMID: 37099132. doi:10.1007/s00259-023-06234-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。